CytoMed Therapeutics (NASDAQ:GDTC) Director Chee Kong Choo Purchases 112,000 Shares of Stock

CytoMed Therapeutics Limited (NASDAQ:GDTC) Director Chee Kong Choo purchased 112,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $1.15 per share, for a total transaction of $128,800.00. Following the completion of the acquisition, the director owned 430,324 shares of the company’s stock, valued at approximately $494,872.60. This trade represents a 35.18% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

CytoMed Therapeutics Stock Up 1.0%

NASDAQ:GDTC opened at $1.15 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17. The business’s 50-day simple moving average is $1.04 and its two-hundred day simple moving average is $1.16. CytoMed Therapeutics Limited has a 52 week low of $0.68 and a 52 week high of $3.68.

CytoMed Therapeutics (NASDAQ:GDTC) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.06) EPS for the quarter. The business had revenue of $0.06 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CytoMed Therapeutics in a report on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.